|
Flamel Technologies SA (NASDAQ:(FLML )), a specialty pharmaceutical company, was set up in 1990 and now is based in Lyon, France. The company sells therapeutic products under GMP guidelines - audited by the United States Food and Drug Administration (FDA) - through its own drug pipeline platforms, Medusa and Micropump. FDA-audited GMP guidelines in France and United States.〔(【引用サイトリンク】title= Company Business Summary )〕 The company acuired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.〔(【引用サイトリンク】 title= About Us )〕 == Operations == Flamel Technologies has a strong partnership with GlaxoSmithKline. In June 2013, Flamel Technologies reached a multi-year partnership agreement with an undisclosed pharmaceutical company, estimating a revenue of over $4 million over the next several years.〔(【引用サイトリンク】title= Flamel Technologies Announces Product Partnership Agreement )〕 In May 2013, Flamel Technologies regained the operating right of two drugs using Trigger Lock® delivery technology. In 1997, the company completed its acquisition of a pharmaceutical production facility located in Bordeaux, France from SmithKline Beecham (SB), and entered into a production agreement with SB.〔(【引用サイトリンク】title=Flamel Technologies S.A. Closes Acquisition of French Pharmaceutical Production Facility from SmithKline Beecham )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Flamel Technologies」の詳細全文を読む スポンサード リンク
|